|
 |
Noms commerciaux |
|
|
Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires
|
|
Accofil |
Allemagne, Belgique, Croatie, Grande Bretagne |
|
Duperan |
Chili |
|
Filgen |
Argentine, Chili |
|
Foltran |
Chili |
|
Granulokine |
Brésil, Grèce, Italie |
|
Hebervital |
Colombie |
|
Inmunef |
Colombie, Mexique |
|
Leucosos |
Colombie |
|
Lioplim |
Chili |
|
Neupogen |
Allemagne, Arabie Saoudite, Australie, Autriche, Belgique, Canada, Chili, Colombie, Danemark, Egypte, Emirats Arabes Unis , Equateur, Espagne, Etats Unis d’Amérique, Finlande, France, Grande Bretagne, Iran, Irlande, Luxembourg, Malaisie, Maroc, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pologne, Portugal, Slovénie, Suède, Suisse, Turquie, Vénézuela |
|
Neutromax |
Argentine |
|
Neutropine |
Argentine |
|
Nivestim |
Allemagne, Belgique, France, Grande Bretagne, Norvège, Pays bas |
|
Ratiograstim |
Allemagne, Autriche, Grande Bretagne, Suède |
|
Tevagrastim |
Allemagne, Belgique, Brésil, Chili, Croatie, Espagne, Grande Bretagne, Norvège, Pays bas, Suède, Suisse |
|
|
 |
 |
Bibliographie : Filgrastim |
|
|
Type |
Source |
| 99 |
Revue |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 |
Revue |
Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 182 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Revue |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 2269 |
Revue |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3128 |
Laboratoire |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3249 |
Revue |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3256 |
Revue |
Burnett B, Radic I.
Stability of Hospira filgrastim following changes to thermal and photic storage conditions.
EJHP 2011 ; 17, 5: 49-56. |
| 3474 |
Laboratoire |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3618 |
Laboratoire |
Filgrastim (Neupogen®) - Summary of Product Characteristics
Amgen 2014 |
| 3828 |
Poster |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
Poster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 4055 |
Revue |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4380 |
Laboratoire |
Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019 |
| 4471 |
Laboratoire |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
| 4521 |
Revue |
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020 |
| 4650 |
Laboratoire |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
|
|
